However, as YB-1 transactivates many growth-promoting genes, and we have shown that it can increase sensitivity to approved agents in BLBC, the question of whether it would also be a potent therapeutic target for this aggressive type of breast cancer is being actively pursued in our laboratory. The gene discussed is YBX1; the disease is breast carcinoma.